Law360, New York ( September 24, 2013, 9:56 AM EDT) -- An important trend is emerging in pharmaceutical settlements with potential long-term ramifications for any company in the government's crosshairs. Now, even if a company pays millions or even billions of dollars to secure a resolution and bring closure to a costly multiyear U.S. Department of Justice investigation, it may nevertheless find itself in a long-term relationship with the DOJ that includes ongoing oversight and the risk of additional penalties. That is the new reality facing life sciences companies grappling with whistleblower-initiated government investigations....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.